Relation Therapeutics is a biotechnology company that focuses on humanizing drug discovery and development. It leverages human genetics and clinical omics data and utilizes patient-derived tissue samples with functional genomics interventional experiments to identify, validate, and prosecute therapeutic programs.
Anagenex is a seed stage biotechnology company building a novel platform for drug discovery focusing on difficult targets.
Ultima Genomics is unleashing the power of genomics at scale. Ultima Genomics drives the scale of genomic information to enable unprecedented advances in biology and improvements in human health. The company was founded in 2016 and is based in Newark, California.
VitroLabs is a startup working on the cutting edge of 3D tissue engineering using stem cell-based technologies. The company develops a fully scalable tissue engineering platform combining the latest breakthroughs in stem cell research and biomaterials. It manufactures real leather without the need to raise and slaughter animals using breakthroughs in stem cell research and tissue engineering. VitroLabs was founded on 2016 and is based in San Jose, California.
By using data, technology, and high quality medical expertise, we aim to deliver an empathetic people-centric healthcare experience that helps people live longer.
Turn.bio is a biotechnology company developing drugs to reverse aging and age-related diseases. Utilizing a patented mRNA platform technology, ERA, the company is combating the effects of aging on the epigenome. The company’s proprietary mRNA platform technology, ERA and eTurna, a delivery platform specifically designed to enable nucleic acid therapeutics, combats the effects of aging in the epigenome, thus restoring optimal gene expression. It focuses on developing tailored therapies targeting indications in immune-related diseases like cancer and dermatological conditions, as well as therapies for ophthalmology, osteoarthritis, and the muscular system.
Volta Labs is a biotechnology company that develops scalable automation for genetic engineering.
Cellino is building a scalable, automated biomanufacturing system for potentially curative personalized cell therapies. Cellino’s vision is to enable healthier lives worldwide with personalized treatments derived from induced pluripotent stem cells (iPSCs), which can serve as the basis for therapies for a host of chronic degenerative diseases, including vision loss and Parkinson's disease.
Faeth Therapeutics is a data-driven, evidence-based company that specializes in mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. It fully focuses on matching specific diets with tumor genotypes and treatment regimens to improve the outcomes of cancer therapy. The company was founded to translate breakthrough discoveries, made by cancer research laboratories, into clinical practice. Its founding team includes some of the industry’s preeminent researchers and clinicians.
NextVivo is a biotech company developing an immune organoid technology platform to transform the future of drug development. Its mission is to accelerate the development of safer, more effective therapies that are generated and tested in immune-competent human-derived models.
Robin Healthcare provides medical scribe services. They help remove barriers to health and improve the doctor-patient experience. They offer technology and trained medical scribes to deliver a seamless experience that integrates directly into the electronic medical record, taking on the administrative burdens of medicine so doctors can reclaim their time and maintain control over their practice.
Sword Health is on a mission to free 2 billion people from pain by pioneering the field of AI Care. It is #1 in clinical and cost-saving outcomes because we have the most advanced AI, developed and overseen by the most clinically rigorous team. Sword has developed the first platform to predict, prevent, and treat pain by starting with the expertise of world-class doctors of physical therapy and then building an interactive AI experience to deliver care that members can use anywhere, anytime, under a clinician’s supervision.
Viome, Inc. is a biotechnology company based in Bellevue, Washington, that specializes in wellness monitoring through at-home clinical-grade testing kits. Founded in 2016, the company combines analyses of blood, urine, saliva, and stool samples to create detailed profiles of an individual's biochemistry and gut microbiome. Utilizing proprietary RNA sequencing technology, Viome assesses the microbial communities in the digestive system and provides users with personalized insights related to their health. The findings are integrated into a smartphone application that offers tailored recommendations for diet and lifestyle adjustments aimed at preventing and reversing chronic diseases. Viome markets its products through various distributors and online platforms, operating as a subsidiary of BlueDot LLC.
By using data, technology, and high quality medical expertise, we aim to deliver an empathetic people-centric healthcare experience that helps people live longer.
House Rx is a health technology platform focused on improving affordability and patient access to specialty medications.
Karma Biotechnologies is a Los Angeles startup dedicated to solving autoimmunity, allergies, and food sensitivities with our Xavine™ precision immunotherapy platform. General immune suppression is still the standard of care for most autoimmune disease patients; there is a critical unmet need to develop antigen-specific therapies that inhibit only the disease-causing rogue immune cells. To meet this need, Karma is leveraging expertise in immunology and lipid nanoparticle engineering to develop tolerogenic immunotherapies that elicit antigen-specific immune tolerance in vivo.
Known Medicine is looking to take the experimentation of how tumors respond to cancer drugs out of the patient’s body and into the lab. The startup breaks down tumor samples into micro tumors, which they treat separately inside specialized micro-environments with different methods and see what works best.
Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California.
Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI.
Even is a health tech company and healthcare provider that partners directly with the top hospitals in the country to offer you unlimited diagnostics, consultations, and 50 lakh worth of hospitalisations all with one monthly subscription cost.
Sword Health is on a mission to free 2 billion people from pain by pioneering the field of AI Care. It is #1 in clinical and cost-saving outcomes because we have the most advanced AI, developed and overseen by the most clinically rigorous team. Sword has developed the first platform to predict, prevent, and treat pain by starting with the expertise of world-class doctors of physical therapy and then building an interactive AI experience to deliver care that members can use anywhere, anytime, under a clinician’s supervision.
Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body. Ochre Bio is within the heart of Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.
Ellipsis Health is an early-stage start-up developing affective computing for existing patient/care team interactions to create a real-time, behavioral health vital sign for each patient. It provides a simple, cost-effective way for health systems to continually screen their patient population for conditions such as depression and get patients the support they need.
Apton Biosystems develops an optical system designed for sequencing and protein detection, using super-resolution to assess molecules spaced closer than a wavelength of light. It enables biomarker discovery, early disease detection, and therapeutic monitoring, advancing preventive health and precision medicine.
Pendulum Therapeutics believes therapies developed using evidence-based microbiome science and DNA sequencing can help heal the body from within. Armed with 13 patents and 42 pending, the company introduced its flagship product Pendulum Glucose Control, a medical probiotic, in 2020 and demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in a published clinical trial. Founded in 2013 by a diverse team of scientists with deep microbiology, biochemistry, computational, and clinical expertise, Pendulum has raised $111 million to date from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures and Mayo Clinic among others. Pendulum Therapeutics is headquartered in San Francisco.
Rightway is a leading technology and services company radically simplifying healthcare for clients and members. Its Care Navigation and new-to-the world PBM platform reimagine the member experience, generate industry-leading engagement, and significantly reduce total cost-of-care.
Scipher Medicine develops a healthcare platform designed to determine which drug will work best for each patient. The company is committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. They are building a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, Scipher Medicine can predict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For its first commercial product, they have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs. Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests are then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.
Inflammatix develops novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system. It is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. They are initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University.
Bionaut Labs revolutionizes the treatment of central nervous system disorders with its precision medicine treatment modality. By creating a new medical modality of remote-controlled micro-robots called Bionauts, the company can transform the way the biopharmaceutical industry develops treatments, allowing them to engineer the therapeutic index for efficacy and maintain safety. Bionaut Labs is focused on helping patients suffering from debilitating brain diseases who have few available treatment options. The anatomical targeting capabilities of the Bionaut platform make new therapeutics technologies such as gene therapy, CRISPR-Cas9, and oncolytic viruses viable in challenging clinical settings.
EGenesis is a biotechnology company developing solid organ and therapeutic cell transplantation to treat diseases. It offers gene editing and genome engineering platform to develop human-compatible organs, tissues, and cells, aiming to provide an alternative solution to the global organ shortage.
Cellino is building a scalable, automated biomanufacturing system for potentially curative personalized cell therapies. Cellino’s vision is to enable healthier lives worldwide with personalized treatments derived from induced pluripotent stem cells (iPSCs), which can serve as the basis for therapies for a host of chronic degenerative diseases, including vision loss and Parkinson's disease.
Ukko is a biotech company improving the lives of millions that suffer from food allergies and disorders. The company's computational engineering platform re-designs food allergens into safe and effective therapeutics that will become best-in-class allergy therapy. Ukko is creating a comprehensive, clinically validated map of the molecular structure of food allergies, revealing critical information about the biological mechanisms that govern human-food interactions. They use the platform to create new versions of proteins that do not elicit an immune response based on this map. These proteins enable a completely new approach to treating protein-based allergies.
Lumiata is transforming the healthcare enterprise through the application of AI. Bringing predictive power within reach of data science teams and business users, we’re driving predictability and precision at scale — empowering providers and payers to reduce risk and manage costs and move out of reliance on flat data into a future of insights. Lumiata machine learning tools and pre-trained models comprise a scalable platform purpose-built for healthcare. Lumiata products are built from more than 120 million patient records, in-depth clinical knowledge, and its proprietary clinical IP. Lumiata enables healthcare organizations to explore use cases such as underwriting and care management. Lumiata is proud to be backed by Khosla Ventures, Blue Venture Fund, Defy.vc, and AllegisNL Capital. Team Lumiata is distributed across Silicon Valley, Dallas, and Guadalajara, Mexico.
Earli is a developer of cancer treatment devices designed to search for natural biomarkers. The company's mission is to make cancer a benign experience. Cancers are detected early when they are homogeneous; and then located early, so they can be treated when the chances of survival are multiple times higher. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology forces cancer cells to make a synthetic, non-human biomarker using a novel gene therapy approach called Synthetic Biopsy. The early cancer is then visible in a PET scanner. The same platform is also usable for therapeutics.
Rubedo Life Sciences is a biopharmaceutical company that is developing a diverse portfolio of innovative therapies that are engineered to target cells that are responsible for chronic age-related diseases. Its proprietary ALEMBIC drug discovery platform has generated novel first-in-class small molecules designed to selectively target senescent cells, which are important in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic diseases. The Rubedo leadership team is made up of industry leaders and pioneers in chemistry, technology, and life sciences, with extensive experience in drug development and commercialization ranging from large pharma to biotech innovators.
SiPhox Health builds next-generation diagnostics infrastructure both for the home and the central lab. The SiPhox Health at-home test kit assesses 17 blood biomarkers related to inflammation, hormonal health, metabolic fitness, and cardiovascular health.
Caption Health will use this funding to scale up its commercial operations, continue to develop its AI technology platform and form new partnerships. As more providers adopt the Caption AI platform, the company plans to add new clinical capabilities to expand the use of Caption AI in additional care settings.
Menten AI designs new protein drugs and enzymes using quantum computers and machine learning. Proteins are large molecules that can twist into many shapes. Discovering the right shape for a protein to be a drug or a biocatalyst among almost endless possibilities is a major challenge. Menten AI solves this problem by using machine learning and quantum computing to find better starting points for discovery and further development. Quantum computing makes it possible to represent multiple states of the protein simultaneously and efficiently find the best designs. The team created the world’s first peptide designed on a quantum computer and is now working on peptide therapeutics for oncology and neurodegeneration, as well as on enzymes for industrial applications.
Clear Labs offers next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. The company's platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens and support public health initiatives. The company focuses on delivering actionable insights to enhance safety and operational efficiency in various sectors.
E25Bio specializes in the development of rapid diagnostic tests for epidemic fever viruses. It is dedicated to preventing severe downstream health outcomes with the use of mobile, fast, real-time reporting to create unprecedented large datasets to guide informed and timely responses for the control of disease spread. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Q Bio was founded in 2015 by Jeffrey Kaditz, serial entrepreneur and Founder of Affirm, Dr Michael Snyder, Chair of Genetics and Director of Personalized Medicine and Stanford University, and Dr Garry Choy, physician, radiologist, and former Chief Medical Information Officer at Mass General Hospital. Q Bio is fortunate to be backed by some of the best venture groups in the world including: A16Z, Khosla Ventures, Founders Fund, SciFi VC, and Kevin Durant. This interdisciplinary team based in San Carlos, CA is comprised of pioneers in fields such applied math, computational physics, electrical engineering, genetics, and radiology, hail from a dizzying array of home countries and cultural backgrounds.
Iora Health is dedicated to providing possible service and care for each patient without any of the barriers or excuses that plague the current system. They’ve completely redesigned Primary Care to help patients better manage their health and navigate the health care system. Every patient gets a personal physician as well as a personal health coach who stays in close contact during and between office visits, both of whom are available by email, text, or video in addition to in-person visits. In addition, they provide educational offerings, including group visits, to help patients stay on track with their health goals.
Connie Health empowers older Americans to make confident, worry-free healthcare decisions.
Arpeggio Biosciences leverages state of the art sequencing approaches coupled with powerful machine learning to uncover novel insights into a compound's biological mechanism of action. The company is diverse set of molecular biologists, computer scientists, and biotechnology enthusiasts passionate about understanding where, why, and how therapeutics work.
Inflammatix develops novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system. It is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. They are initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University.
EGenesis is a biotechnology company developing solid organ and therapeutic cell transplantation to treat diseases. It offers gene editing and genome engineering platform to develop human-compatible organs, tissues, and cells, aiming to provide an alternative solution to the global organ shortage.
Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California.
Bionaut Labs revolutionizes the treatment of central nervous system disorders with its precision medicine treatment modality. By creating a new medical modality of remote-controlled micro-robots called Bionauts, the company can transform the way the biopharmaceutical industry develops treatments, allowing them to engineer the therapeutic index for efficacy and maintain safety. Bionaut Labs is focused on helping patients suffering from debilitating brain diseases who have few available treatment options. The anatomical targeting capabilities of the Bionaut platform make new therapeutics technologies such as gene therapy, CRISPR-Cas9, and oncolytic viruses viable in challenging clinical settings.
Pendulum Therapeutics believes therapies developed using evidence-based microbiome science and DNA sequencing can help heal the body from within. Armed with 13 patents and 42 pending, the company introduced its flagship product Pendulum Glucose Control, a medical probiotic, in 2020 and demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in a published clinical trial. Founded in 2013 by a diverse team of scientists with deep microbiology, biochemistry, computational, and clinical expertise, Pendulum has raised $111 million to date from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures and Mayo Clinic among others. Pendulum Therapeutics is headquartered in San Francisco.
Sword Health is on a mission to free 2 billion people from pain by pioneering the field of AI Care. It is #1 in clinical and cost-saving outcomes because we have the most advanced AI, developed and overseen by the most clinically rigorous team. Sword has developed the first platform to predict, prevent, and treat pain by starting with the expertise of world-class doctors of physical therapy and then building an interactive AI experience to deliver care that members can use anywhere, anytime, under a clinician’s supervision.
Cellino is building a scalable, automated biomanufacturing system for potentially curative personalized cell therapies. Cellino’s vision is to enable healthier lives worldwide with personalized treatments derived from induced pluripotent stem cells (iPSCs), which can serve as the basis for therapies for a host of chronic degenerative diseases, including vision loss and Parkinson's disease.
Docbot is an artificial intelligence technology company focusing on gastrointestinal (GI) diseases. Docbot’s products are built on the UltivisionAI software platform for real-time image analysis, automated reporting, and analytic tools to improve patient care and clinical workflows. Docbot's mission is to provide the most powerful AI-assisted image analysis solutions to revolutionize GI care.
BIOAGE discovers and develops drugs to treat aging and associated diseases. The company's primary initiative, azelaprag, is an oral APJ agonist on track for Phase 2 trials in conjunction with tirzepatide to potentially become a groundbreaking treatment for obesity in the elderly.
Eva develops an accessible and non-invasive wearable device designed to detect breast cancer risks. The company's wearable device is equipped with tactile sensors which are designed to map the surface of the breast and surrounding areas, allowing women to keep a track on the changes in breast temperature, size, and weight, with the help of biosensors inside the cup which constantly monitors information.
Nebula Genomics is a human genome sequencing and health big data company on a mission to usher in the era of genomic sequencing by building a large and trusted genomic and health data marketplace for consumers, researchers and the medical community. Using blockchain to ensure that consumers maintain control of their data and are compensated for its use, the Nebula marketplace will aggregate a critical mass of rich genetic information that researchers can analyze in order to accelerate drug development, streamline clinical trials, and usher in the era of truly personalized medicine. The company was founded by Harvard genomics pioneer George Church, along with Harvard researchers Dennis Grishin and Kamal Obbad. Founded in 2017, Nebula Genomics has offices in San Francisco, CA and Boston, MA and is backed by investors including Khosla Ventures, Arch Venture Partners, Fenbushi Capital, Mayfield, F-Prime Capital Partners, GreatPoint Ventures, Hemi Ventures and Mirae Asset.
Scipher Medicine develops a healthcare platform designed to determine which drug will work best for each patient. The company is committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. They are building a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, Scipher Medicine can predict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For its first commercial product, they have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs. Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests are then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.
Lumiata is transforming the healthcare enterprise through the application of AI. Bringing predictive power within reach of data science teams and business users, we’re driving predictability and precision at scale — empowering providers and payers to reduce risk and manage costs and move out of reliance on flat data into a future of insights. Lumiata machine learning tools and pre-trained models comprise a scalable platform purpose-built for healthcare. Lumiata products are built from more than 120 million patient records, in-depth clinical knowledge, and its proprietary clinical IP. Lumiata enables healthcare organizations to explore use cases such as underwriting and care management. Lumiata is proud to be backed by Khosla Ventures, Blue Venture Fund, Defy.vc, and AllegisNL Capital. Team Lumiata is distributed across Silicon Valley, Dallas, and Guadalajara, Mexico.
Viome, Inc. is a biotechnology company based in Bellevue, Washington, that specializes in wellness monitoring through at-home clinical-grade testing kits. Founded in 2016, the company combines analyses of blood, urine, saliva, and stool samples to create detailed profiles of an individual's biochemistry and gut microbiome. Utilizing proprietary RNA sequencing technology, Viome assesses the microbial communities in the digestive system and provides users with personalized insights related to their health. The findings are integrated into a smartphone application that offers tailored recommendations for diet and lifestyle adjustments aimed at preventing and reversing chronic diseases. Viome markets its products through various distributors and online platforms, operating as a subsidiary of BlueDot LLC.
Iora Health is dedicated to providing possible service and care for each patient without any of the barriers or excuses that plague the current system. They’ve completely redesigned Primary Care to help patients better manage their health and navigate the health care system. Every patient gets a personal physician as well as a personal health coach who stays in close contact during and between office visits, both of whom are available by email, text, or video in addition to in-person visits. In addition, they provide educational offerings, including group visits, to help patients stay on track with their health goals.
Q Bio was founded in 2015 by Jeffrey Kaditz, serial entrepreneur and Founder of Affirm, Dr Michael Snyder, Chair of Genetics and Director of Personalized Medicine and Stanford University, and Dr Garry Choy, physician, radiologist, and former Chief Medical Information Officer at Mass General Hospital. Q Bio is fortunate to be backed by some of the best venture groups in the world including: A16Z, Khosla Ventures, Founders Fund, SciFi VC, and Kevin Durant. This interdisciplinary team based in San Carlos, CA is comprised of pioneers in fields such applied math, computational physics, electrical engineering, genetics, and radiology, hail from a dizzying array of home countries and cultural backgrounds.
Lumiata is transforming the healthcare enterprise through the application of AI. Bringing predictive power within reach of data science teams and business users, we’re driving predictability and precision at scale — empowering providers and payers to reduce risk and manage costs and move out of reliance on flat data into a future of insights. Lumiata machine learning tools and pre-trained models comprise a scalable platform purpose-built for healthcare. Lumiata products are built from more than 120 million patient records, in-depth clinical knowledge, and its proprietary clinical IP. Lumiata enables healthcare organizations to explore use cases such as underwriting and care management. Lumiata is proud to be backed by Khosla Ventures, Blue Venture Fund, Defy.vc, and AllegisNL Capital. Team Lumiata is distributed across Silicon Valley, Dallas, and Guadalajara, Mexico.
Catalia Health brings together artificial intelligence, psychology, and medicine to deliver lasting change. We create effective patient engagement and generate unique data of value to our customers. Our cloud-based platform delivers unique conversations to patients to help address their ongoing healthcare issues in an effective way. These messages are delivered through mobile apps, a web interface, and our uniquely engaging (and patented) interactive robotic coach.
Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI.
Viome, Inc. is a biotechnology company based in Bellevue, Washington, that specializes in wellness monitoring through at-home clinical-grade testing kits. Founded in 2016, the company combines analyses of blood, urine, saliva, and stool samples to create detailed profiles of an individual's biochemistry and gut microbiome. Utilizing proprietary RNA sequencing technology, Viome assesses the microbial communities in the digestive system and provides users with personalized insights related to their health. The findings are integrated into a smartphone application that offers tailored recommendations for diet and lifestyle adjustments aimed at preventing and reversing chronic diseases. Viome markets its products through various distributors and online platforms, operating as a subsidiary of BlueDot LLC.
Ukko is a biotech company improving the lives of millions that suffer from food allergies and disorders. The company's computational engineering platform re-designs food allergens into safe and effective therapeutics that will become best-in-class allergy therapy. Ukko is creating a comprehensive, clinically validated map of the molecular structure of food allergies, revealing critical information about the biological mechanisms that govern human-food interactions. They use the platform to create new versions of proteins that do not elicit an immune response based on this map. These proteins enable a completely new approach to treating protein-based allergies.
Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics, and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.
Twine Health is a cloud-based collaborative care platform for chronic disease management. It consists of a patient engagement portal, a peer support network, a care management solution, and an outcome analytics tool. The platform enables users to co-create personalized care plans that serve as common ground for collaboration with their care team: their own providers such as physicians and nurse practitioners; their family and friends; and coaches such as nurses, pharmacists, health coaches, and more. Twine Health was developed at the MIT Medical Lab by John Moore and Frank Moss and its operations are based in Massachusetts, United States.
Catalia Health brings together artificial intelligence, psychology, and medicine to deliver lasting change. We create effective patient engagement and generate unique data of value to our customers. Our cloud-based platform delivers unique conversations to patients to help address their ongoing healthcare issues in an effective way. These messages are delivered through mobile apps, a web interface, and our uniquely engaging (and patented) interactive robotic coach.
Inflammatix develops novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system. It is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. They are initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University.
EGenesis is a biotechnology company developing solid organ and therapeutic cell transplantation to treat diseases. It offers gene editing and genome engineering platform to develop human-compatible organs, tissues, and cells, aiming to provide an alternative solution to the global organ shortage.
Clear Labs offers next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. The company's platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens and support public health initiatives. The company focuses on delivering actionable insights to enhance safety and operational efficiency in various sectors.
Caption Health will use this funding to scale up its commercial operations, continue to develop its AI technology platform and form new partnerships. As more providers adopt the Caption AI platform, the company plans to add new clinical capabilities to expand the use of Caption AI in additional care settings.
BioConsortia is developing highly effective microbial consortia for increasing agricultural yields. Soil and plant-associated microbes interact with and supplement the functions encoded by the crop genome. Opportunities abound to exploit these plant-microbe interactions but overwhelming complexity and the huge amount of genetic diversity have hindered the realization of these by conventional R&D methods. BioConsortia has developed a revolutionary Advanced Microbial Selection (AMS) process for crop trait enhancement that uses iterative rounds of plant phenotyping and selection to co-select for beneficial changes in the microbiome. Isolates are obtained from the microbiome of plants expressing the desired traits and are developed as consortia for application as a commercial seed treatment, drench, or granule product. We have a pipeline of products for increased fertilizer utilization, growth improvement, and other beneficial crop traits, such as abiotic tolerance and enhanced metabolite expression.
Iora Health is dedicated to providing possible service and care for each patient without any of the barriers or excuses that plague the current system. They’ve completely redesigned Primary Care to help patients better manage their health and navigate the health care system. Every patient gets a personal physician as well as a personal health coach who stays in close contact during and between office visits, both of whom are available by email, text, or video in addition to in-person visits. In addition, they provide educational offerings, including group visits, to help patients stay on track with their health goals.
Lumiata is transforming the healthcare enterprise through the application of AI. Bringing predictive power within reach of data science teams and business users, we’re driving predictability and precision at scale — empowering providers and payers to reduce risk and manage costs and move out of reliance on flat data into a future of insights. Lumiata machine learning tools and pre-trained models comprise a scalable platform purpose-built for healthcare. Lumiata products are built from more than 120 million patient records, in-depth clinical knowledge, and its proprietary clinical IP. Lumiata enables healthcare organizations to explore use cases such as underwriting and care management. Lumiata is proud to be backed by Khosla Ventures, Blue Venture Fund, Defy.vc, and AllegisNL Capital. Team Lumiata is distributed across Silicon Valley, Dallas, and Guadalajara, Mexico.
Forward is a startup redesigning the way healthcare is delivered using all the technologies healthcare has neglected such as sensors, mobile, and AI. Forward was founded in January 2016 by former executives and engineering leaders from Google and Uber and led by serial entrepreneur Adrian Aoun. Forward is funded by investors and entrepreneurs including First Round Capital, Eric Schmidt (Google/Alphabet chairman), Marc Benioff (Salesforce founder), Joe Lonsdale (Palantir founder), Joshua Kushner (Oscar co-founder), and Garrett Camp (Uber co-founder).
Pendulum Therapeutics believes therapies developed using evidence-based microbiome science and DNA sequencing can help heal the body from within. Armed with 13 patents and 42 pending, the company introduced its flagship product Pendulum Glucose Control, a medical probiotic, in 2020 and demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in a published clinical trial. Founded in 2013 by a diverse team of scientists with deep microbiology, biochemistry, computational, and clinical expertise, Pendulum has raised $111 million to date from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures and Mayo Clinic among others. Pendulum Therapeutics is headquartered in San Francisco.
Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics, and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.
Twine Health is a cloud-based collaborative care platform for chronic disease management. It consists of a patient engagement portal, a peer support network, a care management solution, and an outcome analytics tool. The platform enables users to co-create personalized care plans that serve as common ground for collaboration with their care team: their own providers such as physicians and nurse practitioners; their family and friends; and coaches such as nurses, pharmacists, health coaches, and more. Twine Health was developed at the MIT Medical Lab by John Moore and Frank Moss and its operations are based in Massachusetts, United States.
Clear Labs offers next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. The company's platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens and support public health initiatives. The company focuses on delivering actionable insights to enhance safety and operational efficiency in various sectors.
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.
Catalia Health brings together artificial intelligence, psychology, and medicine to deliver lasting change. We create effective patient engagement and generate unique data of value to our customers. Our cloud-based platform delivers unique conversations to patients to help address their ongoing healthcare issues in an effective way. These messages are delivered through mobile apps, a web interface, and our uniquely engaging (and patented) interactive robotic coach.
At 20n, They use algorithms to engineer microbes. Specifically, their algorithms engineer microbes to make chemicals. Like yeast produces alcohol during beer brewing, their engineered microbes will produce chemicals with therapeutic health and industrial biotech applications. The best illustration of this DARPA-backed technology is the bacteria They engineered to produce Paracetamol (also known as acetaminophen, and sold under the brand name Tylenol). Aside from this bacteria, there is no known natural way of producing acetaminophen. They are building data mining technology that will allow us to enable the bioproduction of a whole spectrum of valuable molecules. Below is the map of every chemical that can be made biologically, as discovered by 20n's algorithms.
Apton Biosystems develops an optical system designed for sequencing and protein detection, using super-resolution to assess molecules spaced closer than a wavelength of light. It enables biomarker discovery, early disease detection, and therapeutic monitoring, advancing preventive health and precision medicine.
Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics, and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.
Caption Health will use this funding to scale up its commercial operations, continue to develop its AI technology platform and form new partnerships. As more providers adopt the Caption AI platform, the company plans to add new clinical capabilities to expand the use of Caption AI in additional care settings.
Iora Health is dedicated to providing possible service and care for each patient without any of the barriers or excuses that plague the current system. They’ve completely redesigned Primary Care to help patients better manage their health and navigate the health care system. Every patient gets a personal physician as well as a personal health coach who stays in close contact during and between office visits, both of whom are available by email, text, or video in addition to in-person visits. In addition, they provide educational offerings, including group visits, to help patients stay on track with their health goals.
Alchemist is a venture-backed accelerator focused on accelerating the development of seed-stage ventures that monetize from enterprises (not consumers). CB Insights rated Alchemist the top accelerator in 2016 based on the median funding rates of its grads (YC was #2). The accelerator’s primary screening criteria is on teams, prioritizing having distinctive technical co-founders. The organization provides seed investment into companies it admits (typically $36K), and provides founders a structured path to traction, fundraising, mentorship, and community throughout a 6-month program. The company's backers include many of the top corporate and VC funds in the Valley -- including Khosla Ventures, DFJ, Cisco, GE, next47(Siemens), and Salesforce, among others—the accelerator seeds around 75 enterprise-monetizing ventures/year. Notable alumni include LaunchDarkly, Rigetti Quantum Computing, mPharma, Matternet, and Mightyhive.
Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics, and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.
BioConsortia is developing highly effective microbial consortia for increasing agricultural yields. Soil and plant-associated microbes interact with and supplement the functions encoded by the crop genome. Opportunities abound to exploit these plant-microbe interactions but overwhelming complexity and the huge amount of genetic diversity have hindered the realization of these by conventional R&D methods. BioConsortia has developed a revolutionary Advanced Microbial Selection (AMS) process for crop trait enhancement that uses iterative rounds of plant phenotyping and selection to co-select for beneficial changes in the microbiome. Isolates are obtained from the microbiome of plants expressing the desired traits and are developed as consortia for application as a commercial seed treatment, drench, or granule product. We have a pipeline of products for increased fertilizer utilization, growth improvement, and other beneficial crop traits, such as abiotic tolerance and enhanced metabolite expression.